Results 101 to 110 of about 56,993 (185)

Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case report. [PDF]

Ann Med Surg (Lond), 2016
Yamaguchi T, Ohyama S, Furukawa H, Sato N, Ohnishi I, Kasashima S, Kawashima A, Kayahara M.   +7 more
europepmc   +1 more source

Effects of Sevelamer Hydrochloride on Uremic Toxins Serum Indoxyl Sulfate and P-Cresyl Sulfate in Hemodialysis Patients. [PDF]

J Clin Med Res, 2017
Lin CJ, Pan CF, Chuang CK, Liu HL, Huang SF, Chen HH, Wu CJ.   +6 more
europepmc   +1 more source

Biomechanical properties of bones from rats treated with sevelamer [Biomehanička svojstva kostiju štakora tretiranih sevelamerom] [PDF]

, 2011
Sevelamer hydrochloride is used for ten years in patients on dialysis as a phosphate binder. We have previously shown that oral application of sevelamer prevents the bone loss and increases the bone volume in ovariectomized rats. In this study we further
Tikvica, Ana, Brnčić, Mladen, Vukičević, Slobodan, Drača, Nataša, Eljuga, Domagoj, Semenski, Damir   +5 more
core  

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. [PDF]

Nephrology (Carlton), 2017
Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T.   +4 more
europepmc   +1 more source

Clinical Evaluation of Low-Dose Magnesium Carbonate as a Phosphate Binder in Chronic Hemodialysis Patients. [PDF]

Life (Basel)
Tzekov V, Kostadinova T, Artinyan E, Stoyanova R, Valcheva E, Dimov N.   +5 more
europepmc   +1 more source

New Drugs: Sevelamer hydrochloride

Australian Prescriber, 2005
openaire   +1 more source

doi: 10.1093/ndt/gfq292

, 2010
Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and ...
Pedro Ponce, Michael Leidig, Jutta Passlick-deetjen, Angel L. M. De Francisco, Adrian C. Covic, Markus Ketteler, Ewa Benedyk-lorens, Caecilia Scholz, Gabriel M. Mircescu   +8 more
core  

Serum activin A and bone metabolism in patients undergoing hemodialysis. [PDF]

Osteoporos Int
Nakagawa Y, Takahashi H, Takahashi Y, Hyodo T, Hida M, Suga T, Kakuta T, Tomita Y, Nakamura M, Komaba H.   +9 more
europepmc   +1 more source

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials. [PDF]

PLoS One
Nagano N, Tokunaga S, Asada S, Fukagawa M, Akizawa T.   +4 more
europepmc   +1 more source

Assessing the real-world drug safety of sevelamer for hyperphosphatemia: Insights from a comprehensive analysis of the FDA adverse event reporting system (FAERS) database. [PDF]

Medicine (Baltimore)
Shao X, Yang H, Tan C, Liu J, Zhou L.
europepmc   +1 more source